2017-12-20 19:49:54 UTC

Talking With Your IBD Patients About Biosimilars


.25 hours


In this on-demand video series, Sophie Balzora, MD, will provide an overview of the concerns patients may have about biosimilar therapies, and how best to address those concerns. Role-play is provided to demonstrate how to have conversations with your patients who may be beginning treatment with biosimilars, or are considering switching to a biosimilar. This activity is a collaboration of the AGA Institute and the Crohn's and Colitis Foundation.

Please note that this video mentions one biosimilar, infliximab-dyyb, which has been approved for licensure for use of all indications of which infliximab has been approved. As of Dec. 15, 2017, there are three therapies biosimilar to infliximab that have been approved for treatment of inflammatory bowel disease (IBD): infliximab-abda, infliximab-dyyb and infliximab-qbtx.

This program is supported by independent educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Pfizer.

Who Should Take this Course

This activity is intended for gastroenterologists, GI fellows, nurse practitioners, physician assistants and other health care professionals who treat GI disorders.

Learning Objectives

At the conclusion of this presentation, learners will:

  • Identify approaches to educating and discussing the topic of biosimilars with patients.
  • Anticipate common questions from patients about safety, appropriate use and cost (based on real patient questions received).
  • Employ best practices in shared decision-making to determine appropriate course of treatment with patient.


Video #1: Talking With Your IBD Patient About Starting Biosimilars

Video #2: Talking With Your IBD Patient About Switching to Biosimilars

Claim CME

CME/Maintenance of Certification (MOC) Information

The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The AGA Institute designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.

Successful completion of this CME activity enables the participant to earn up to .25 MOC points in the American Board of Internal Medicine’s (ABIM) MOC program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

CME/MOC expiration date: Dec. 22, 2018

If you have any questions, please email education@gastro.org

Faculty Relationship and Financial Disclosures

View financial disclosures for presenters, planning committee and staff


Sophie Balzora, MD, NYU School of Medicine

Kait Scalisi

Planning Committee

Gary R. Lichtenstein, MD, AGAF, University of Pennsylvania

AGA Staff

Sandra Amos

Maura H. Davis

Monique S. Dyson, MS, CHES

Aimee Frank

Hannah Herrington, MPH, CHES

Alison Kim, PhD

Diana Tsuji, CHES

Crohn’s & Colitis Foundation Staff

Orna Ehrlich

Anzee Sharp

Catherine Soto

Laura Wingate

More on Biosimilars

Course for APPs benefits all experience levels

April 16, 2018

AGA's popular course for advanced practice providers will take place Aug. 10 through 12 in Chicago, Illinois.

Overview of the Regulatory Framework and FDA’s Guidance for the Development and Approval of Biosimilar and Interchangeable Products in the US

April 3, 2018

In this on-demand webinar, Sue Lim, MD provides an overview of the background, terminology and general requirements for biosimilar and interchangeable product applications.

The Development and Approval of Inflectra, a Biosimilar to Remicade: Case Presentation

April 3, 2018

In this on-demand webinar, Sue Lim, MD of the FDA provides a general review of the requirements for a biosimilar 351(k) application and discusses the approval process for Inflectra.